Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Orchestra BioMed Holdings's annualizedNet Income for the quarter that ended in Jun. 2026 was $-95.02 Mil. Orchestra BioMed Holdings's average total tangible assets for the quarter that ended in Jun. 2026 was $108.18 Mil. Therefore, Orchestra BioMed Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was -87.84%.
The historical rank and industry rank for Orchestra BioMed Holdings's Return-on-Tangible-Asset or its related term are showing as below:
OBIO'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -89.17 Med: -58.84 Max: -51.49
Current: -61.64
During the past 6 years, Orchestra BioMed Holdings's highest Return-on-Tangible-Asset was -51.49%. The lowest was -89.17%. And the median was -58.84%.
OBIO's Return-on-Tangible-Asset is ranked worse than 66.36% of 1412
companies
in the Biotechnology industry
Industry Median: -35.71
vs OBIO: -61.64
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Orchestra BioMed Holdings Return-on-Tangible-Asset Related Terms
Orchestra BioMed Holdings Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Orchestra BioMed Holdings's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OBIO vs CYDY, IRD, VNDA: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Orchestra BioMed Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchestra BioMed Holdings Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Orchestra BioMed Holdings's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of -87.84% mean?
Orchestra BioMed Holdings (OBIO) has a Return-on-Tangible-Asset of -87.84% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Orchestra BioMed Holdings and its competitors. According to the industry distribution chart, Orchestra BioMed Holdings ranks #937 out of 1412 companies in the Biotechnology industry, placing it in the top 66.4%.
Is Orchestra BioMed Holdings' Return-on-Tangible-Asset too high?
Orchestra BioMed Holdings' current Return-on-Tangible-Asset is -87.84%. Based on the distribution chart, Orchestra BioMed Holdings ranks #937 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Orchestra BioMed Holdings has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Orchestra BioMed Holdings' Return-on-Tangible-Asset compare to CYDY and IRD?
According to the Biotechnology industry distribution chart, Orchestra BioMed Holdings ranks #937 out of 1412 companies for Return-on-Tangible-Asset. This places Orchestra BioMed Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Orchestra BioMed Holdings and its competitors. Orchestra BioMed Holdings's current Return-on-Tangible-Asset is -87.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchestra BioMed Holdings stock overvalued right now?
Based on GuruFocus' analysis, Orchestra BioMed Holdings (OBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $31.58, compared to a current price of $5.81 — trading 81.6% below its estimated fair value. The current Return-on-Tangible-Asset is -87.84%. Orchestra BioMed Holdings' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Orchestra BioMed Holdings (OBIO), the current Return-on-Tangible-Asset is -87.84% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchestra BioMed Holdings (OBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Orchestra BioMed Holdings stock appears to be undervalued.
The current stock price of $5.81 is trading 81.6% below its estimated GF Value™ of $31.58.
GuruFocus considers Orchestra BioMed Holdings to be Possible Value Trap.
Key valuation signals for OBIO:
Return-on-Tangible-Asset: -87.84%
GF Value™: $31.58 vs. price of $5.81 (81.6% below fair value)
No single metric tells the full story. See the OBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
42GF Score
Get the complete analysis for OBIO
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OBIO has been successfully added to your 
